Paige Appoints New Leadership to Further Drive Innovation, Bring Artificial General Intelligence to Pathology, and Expand Access to AI Applications
15 Agosto 2024 - 9:00AM
Business Wire
Paige, a leader in next-generation AI technology, today
announced a strategic shift to further advance the role and impact
of AI in cancer care. This initiative includes leveraging its AI
technology to bring Artificial General Intelligence (AGI) to
pathology and oncology, as well as transitioning its diagnostic AI
applications from being exclusive to the Paige Platform to a
standalone solution compatible with other digital pathology
platforms.
To lead this initiative, Razik Yousfi has been appointed Chief
Technology Officer and Chief Executive Officer. Razik has been with
Paige since 2019, playing a key role in product development, data
science, and technology strategy. As Senior Vice President of
Technology, he guided the organization in creating and launching
Paige’s innovative technologies.
Making a Real-World Impact with AI Technology
Under Razik’s leadership, Paige will intensify its focus on
developing next-generation AI to ultimately bring AGI to pathology
and oncology. This approach solidifies Paige’s position as a
foundational force in the techbio industry, providing essential
technology that will drive future advancements in cancer diagnosis
and treatment.
“Paige has always been at the forefront of integrating AI into
pathology. This strategic move reflects our dedication to pushing
the boundaries of what is possible, not only in pathology but also
in support of pharma and oncology companies developing new
diagnostic, prognostic, and predictive tests,” said Razik Yousfi,
CTO and CEO of Paige. “By focusing our efforts on advancing AI for
cancer care and expanding the accessibility of our diagnostic AI
applications, we will set new standards and profoundly impact
patient treatments and outcomes.”
“Every aspect of solving for cancer—detection, diagnosis, and
treatment—begins with the pathological understanding of cancerous
tissue. Paige delivers unparalleled insights, solving complex
problems with precision. It unlocks deep understanding and
discoveries that can inform clinicians, researchers, innovators,
drug developers and more,” said Dr. David Klimstra, Founding Chief
Medical Officer.
Expanding Access to Diagnostic AI Applications
Since its founding in 2017, Paige has been a leader in digital
pathology, earning the first FDA approval and an additional
breakthrough designation for its AI applications. Developed to
assist pathologists in cancer detection and diagnosis, Paige’s
Diagnostic AI alleviates time and resource pressures by automating
traditionally burdensome tasks while delivering high-quality
diagnoses with remarkable sensitivity and specificity, thereby
enhancing diagnostic confidence. Peter Hamilton, former Chief
Operating Officer, has been appointed General Manager of
Diagnostics to drive the integration and expansion of Paige’s
diagnostic AI portfolio.
“Having built the world’s strongest diagnostic AI solutions, we
now want to make them available to cancer patients globally through
partnerships with other digital pathology providers,” said Peter
Hamilton, General Manager of Diagnostics of Paige. “We are excited
to see the convergence of technologies and industries in the
digital pathology and AI space and to bring our groundbreaking AI
capabilities to those who need them most by expanding our
distribution channels and reaching as many cancer patients as
possible.”
About Paige
Paige is pushing the boundaries of AI to solve cancer’s most
critical issues, revolutionizing cancer care with next-generation
technology. By leveraging exclusive access to millions of digitized
pathology slides, clinical reports, and genomic data from Memorial
Sloan Kettering Cancer Center, Paige gains a holistic understanding
of cancer, encompassing diverse factors such as gender, race,
ethnicity, and geographical regions. This comprehensive data
enables Paige to create advanced AI solutions that redefine cancer
detection, diagnosis, and treatment. With a unique, intricate
understanding of tissue, Paige sets new standards in precision
diagnostics, earning the distinction of being the first
FDA-approved AI application in pathology. Paige has also developed
the first million-slide foundation model for cancer, continuing to
lead the way in uncovering novel insights and transforming them
into life-changing products. For more information, visit
www.paige.ai.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240815046354/en/
For Media Cindi Goodsell | Stanton cgoodsell@stantonprm.com